MedPath

Hetrombopag

Generic Name
Hetrombopag
Drug Type
Small Molecule
Chemical Formula
C25H22N4O5
CAS Number
1257792-41-8
Unique Ingredient Identifier
9WGT51BDDL

Overview

Hetrombopag is under investigation in clinical trial NCT03976882 (Hetrombopag for the Treatment of Chemotherapy-induced Thrombocytopenia in Subjects With Malignancy.).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/06/04
N/A
ENROLLING_BY_INVITATION
Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
2025/02/11
Not Applicable
Recruiting
Beijing Children's Hospital
2024/08/20
Phase 4
Recruiting
The Third People's Hospital of Chengdu
2024/06/27
Phase 2
Recruiting
2024/05/30
Phase 2
Recruiting
2023/10/25
Phase 2
Not yet recruiting
2023/09/14
Phase 2
Not yet recruiting
2023/08/01
Phase 2
Not yet recruiting
Sun Yat-sen University
2023/07/13
Phase 2
Not yet recruiting
2023/07/13
Phase 2
Recruiting
Shandong University

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.